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Abstract: Atherosclerosis is a long-term, chronic inflammatory disease of the vessel wall leading to the
formation of occlusive or rupture-prone lesions in large arteries. Complications of atherosclerosis can
become severe and lead to cardiovascular diseases (CVD) with lethal consequences. During the last
three decades, chemokines and their receptors earned great attention in the research of atherosclerosis
as they play a key role in development and progression of atherosclerotic lesions. They orchestrate
activation, recruitment, and infiltration of immune cells and subsequent phenotypic changes, e.g.,
increased uptake of oxidized low-density lipoprotein (oxLDL) by macrophages, promoting the
development of foam cells, a key feature developing plaques. In addition, chemokines and their
receptors maintain homing of adaptive immune cells but also drive pro-atherosclerotic leukocyte
responses. Recently, specific targeting, e.g., by applying cell specific knock out models have shed
new light on their functions in chronic vascular inflammation. This article reviews recent findings on
the role of immunomodulatory chemokines in the development of atherosclerosis and their potential
for targeting.
Keywords: chemokines; inflammation; atherosclerosis; mouse models; chemokine receptors; cardio-
vascular disease
1. Introduction
Chemokines are a large class of secreted cytokines with the capability of inducing
cellular migration by forming chemoattractant gradients, a process also known as chemo-
taxis [1]. This special ability allows chemokines to perform central tasks in the development
and maintenance of the immune system as well as the execution of dynamic inflamma-
tory processes, such as immune cell recruitment. Moreover, chemokines are of prime
importance in embryogenesis and a number of vital cellular functions including, but not
limited to, proliferation, survival and differentiation [2]. Besides their fundamental bene-
fits, chemokines are recognized to play key roles in the pathogenesis of inflammatory and
autoimmune diseases as well as tumor progression. This review will focus on the diverse
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roles of chemokines in atherosclerosis, a chronic inflammatory disease of the vessel wall
that lays the foundation to cardiovascular diseases (CVDs).
Atherosclerosis is a multifaceted disease, which develops and progresses over a long
period of time and eventually leads to severe harm in the vascular tissue. It initially
arises due to a damage to the endothelial lining of large vessels triggered by pathogenic
factors, such as hyperlipidemia and hemodynamic shear stress [3]. Damaged endothelium
becomes activated and initiates an inflammatory response in order to recruit immune cells
to the site of injury. In order to do so, endothelial cells (ECs) secrete chemokines, such
as CXCL1, to be sensed and tracked back to the site of injury by the immune cells. The
aim of these immune cells, primarily classical monocytes, is to enter the sub-endothelial
space to subsequently eliminate the factors that are damaging the endothelium, such as
oxidized low-density lipoprotein (oxLDL). It is well known that LDL breaches the arterial
wall in cases of excessive cholesterol presence in the blood and it becomes oxidized in the
sub-endothelial space. This triggers an inflammatory response in the vascular endothelium
leading to a cascade of atherosclerotic events [4]. Invasion of the arterial wall by leukocytes
is one of the key drivers of atherosclerotic lesion development and it involves several stages,
such as recruitment, adhesion and trans-endothelial infiltration of the cells. These processes
are aided by a variety of chemokines, like CXCL1 and CCL2. Post-infiltration, monocytes
differentiate into macrophages in the intima in order to engulf and clear oxLDL. The latter
has also been shown to be regulated by other chemokines, such as the CXCL12 [5]. Lipid
engulfing macrophages eventually become overloaded and turn into foam cells, which form
the fatty streaks observed in atherosclerotic lesions. Hence, chemokines widely contribute
to many aspects of the pathogenesis and progression of atherosclerotic lesions [6]. Besides
the initiation and growth of the lesions, chemokines can also modulate the stability of the
lesions. Smooth muscle cells (SMCs) produce collagen and elastin, which form a so-called
‘fibrous cap’ around the lesions in order to keep the lesions stable and to prevent rupture.
In addition to lesional collagen content, fibrous cap thickness is a good indicator of lesion
stability and it can be influenced by chemokines, such as CXCL10, among other factors,
like matrix metalloproteinases [7]. Thinning of the fibrous cap and rupturing of the lesions
may lead to thrombus formation and thereby occlude arteries resulting in the disruption
of blood flow to downstream tissues and thereby lead to ischemia related severe clinical
consequences, such as heart attack and stroke. Understanding in what ways chemokines
contribute to the progression of atherosclerosis may help researchers identify and establish
key steps to effectively prevent or treat CVD. Nonetheless, due to the abundance of the
chemokines and chemokine receptors in cells, as well as the richness of their functions, this
task implicates enormous complexity. It is important to note that a chemokine/receptor
axis may be beneficial in various aspects whilst contributing to atherosclerotic events.
In this regard, treatment approaches targeting blockade of certain chemokine axis may
introduce unwanted side-effects and cell specific targeting should be one of the main future
roads to explore.
Chemokines can be classified into four structural groups based on their cysteine
residue order: CC, CXC, CX3C, and XC [8]. They induce cell responses by signaling
through seven-transmembrane G-protein coupled receptors (GPCRs), which are known as
the ‘classical’ chemokine receptors, as well as atypical chemokine receptors (ACKRs), which
are similar to GPCRs but cannot signal through G-proteins [9]. The role of chemokines
and their receptors in atherosclerosis is being investigated via several methods including
genetic and pharmacologic manipulations of these molecules. For example, vascular injury
induced or diet-induced atherosclerotic mouse models, such as apolipoprotein-E deficient
(ApoE−/−) or low-density lipoprotein receptor deficient (Ldlr−/−) mice on Western type
diets are applied. These mice are also genetically modified resulting in lack of certain
chemokines or chemokine receptors (systemically or in a cell-specific manner) in order to
investigate the role of the target molecules in the context of the atherosclerosis. Another
approach serving the same purpose is pharmacological inhibition or enhancement of the
activity of the chemokines and their receptors. Several studies applying these methods have
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shown significant roles of certain chemokines in atherosclerosis; here we will provide a
concise overview (Figures 1 and 2) of these findings and list important chemokine/receptor
axes in the context of atherosclerosis (Table 1).
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Figure 1. Schematic and simplified overview of the effects that chemokine-chemokine receptor axis have on leukocyte
recruitment. Various chemokines and chemokine receptors are visualized that play a role in leukocyte recruitment. Activated
endothelial cells secrete a wide variety of chemokines that attract leukocytes like monocytes and neutrophils towards
the vessel wall in a process called chemotaxis, followed by tethering, rolling and transmigration. Furthermore, activated
macrophages secrete chemokines that stimulate this leukocyte recruitment process and it has been shown that chemokine
rec ptors influenc endothelial permeability, which is an important aspect for leukocyte transmigration (Created with
Biorender.com).
1.1. CCL2-CCR2
CCL2, also known as the monocyte chemoattractant protein-1 (MCP-1), is a potent in-
flammatory chemokine and signals through its receptor CCR2 [10]. Its acute inflammatory
effects were studied in an in-vivo model using CCL2-deficient mice with a thioglycollate
induced peritonitis [11]. Whilst the control mice exhibited significant increases (as high as
a six-fold surge) in the numbers of monocytes and macrophages in their peritoneal cavities,
CCL2-deficient mice displayed a comparatively reduced cell recruitment (two-fold) in
response to the inflammation. It was also observed that the surge in the peritoneal cavity
cell numbers of the control mice was mainly due to monocytes and macrophages with a
small number of neutrophils and eosinophils, whereas CCL2-deficient mice seemed to lack
monocyte and macrophage recruitment whereas showing a similar increase in neutrophils
and eosinophils as observed in control mice.
Strong evidence as early as 1998 established a pro-atherosclerotic role of the CCL2/CCR2
axis. An in-vivo atherosclerosis study using CCL2-deficient Ldlr−/− mice on a long
term high cholesterol diet (≥12 weeks) revealed significantly reduced lipid deposition
in the aortas of CCL2-deficient mice along with fewer macrophages infiltrating into the
aortic walls compared to the control mice [12]. Confirming these observations, another
study showed that CCR2-deficient ApoE−/− mice exhibited significantly reduced lesion
formation as well [13]. The authors likewise showed that the aortas of CCR2-deficient mice
contained less macrophages compared to control mice and concluded that the CCL2–CCR2
axis was important in the monocyte/macrophage accumulation in the vessel wall. This
conclusion was backed up in 1999 via similar findings from Dawson et al [14]. and another
study in 2003 revealed direct evidence that leukocyte specific CCR2-deficiency massively
reduced atherosclerotic lesions via a CCR2-deficient bone marrow cell transplantation
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study in ApoE3-Leiden mice [14,15]. Such reproducible results through different types of
atherosclerotic mouse models well established that the CCL2-CCR2 axis is a strong driver
of atherosclerosis and makes it an important target to study in atherosclerosis.
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Figure 2. Schematic and simplified overview of the effects that chemokine-chemokine receptor axis have on atherosclerotic
processes inside the vessel wall. In the vessel wall, various chemokines and chemokine receptors play an important role in
cellular processes. Secreted chemokines contribute to the leukopedesis and stimulates foam cell formation. Furthermore,
chemokines contribute to macrophage polarization and the formation of neutrophil extracellular traps (NETs). Besides effects
on myeloid cells, also lymphocytes are affected as dendritic cell mediated T cell activation is stimulated by chemokines.
Finally, chemokine and chemokine receptors contribute to smooth muscle cell (SMC) proliferation, lipid uptake and release
of matrix metalloproteases. (Created with Biorender.com) .
Recently, researchers discovered that myeloid cell recruitment to atherosclerotic le-
sions was regulated in a circadian rhythmic fashion and that the myeloid cells deposited
CCL2 onto the arterial wall in order to facilitate adhesion to the endothelium [16]. Ref. [16]
According to the 4-week high-fat diet study, pharmacological blockade of CCR2 via its an-
tagonist RS102895 in a timed manner, targeting the peak of CCL2-CCR2 driven myeloid cell
adhesion to the arterial wall, abolished the adhesion and resulted in decreased atheroscle-
rotic lesion sizes along with diminished lesional macrophage accumulation. Besides these
roles of CCL2, others have also shown its importance in neointimal hyperplasia forma-
tion [17]. In a cuff-induced arterial injury study, CCR2-deficient mice exhibited significantly
less neointimal hyperplasia compared to control mice [18]. A similar study further con-
firmed that arteries from CCR2 deficient mice showed above 60% reduction in the intimal
area as well as intima/media ratio compared to control mice after four weeks of injury [19].
Hence, CCL2 plays an essential role in monocyte trafficking and results suggest that the
CCL2-CCR2 axis may be an important target to treat acute arterial injury and complications,
such as restenosis in CVD patients.
1.2. CCL3
Neutrophils are potent inflammatory short acting cells associated with increased intimal
apoptosis and a proinflammatory phenotype [20]. It is thought that neutrophil infiltration
induces plaque destabilization due to enhanced inflammation, intimal apoptosis, necrotic
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core formation, and matrix degradation. CCL3 interacts with chemokine receptors CCR4,
CCR1 and CCR5, of which the latter two have been implicated in atherogenesis and are
found on neutrophils [21]. Activated macrophages are the main source of CCL3, however
it can also be released by activated platelets, neutrophils, and mast cells [22,23]. A previous
study has shown that CCL2 and CCL3 induce an inflammatory cascade regulating firm
adherence and infiltration of neutrophils [24]. Thus, CCL3 may play an important role in
neutrophil recruitment and the development of atherosclerosis. In a bone marrow trans-
plant experiment where irradiated Ldlr−/− mice were transplanted with either CCL3−/− or
Ldlr−/− bone marrow and fed a western diet (WD) for 12 weeks, resulted in reduced CCL3
release in response to LPS treatment suggesting leukocytes are a critical source of CCL3.
Furthermore, hematopoietic CCL3-deficiency significantly reduced aortic lesion formation
by 31%, moreover neutrophil adhesion to and presence in plaques was significantly attenu-
ated [25]. This demonstrates that under inflammatory conditions leukocyte-derived CCL3
can induce neutrophil chemotaxis toward the atherosclerotic plaque, thereby accelerating
lesion formation.
However, the role of CCL3 in atherosclerosis may be dependent on the various recep-
tors as deficiency of CCR1 in ApoE−/− mice fed a WD for 10 to 12 weeks led to accelerated
atherosclerosis and greater plaque size and infiltration of T lymphocytes [21]. However,
functional deficiency of CCR5 in ApoE−/− mice was shown to reduce atherosclerotic lesion
development, and plaques contained less macrophages and T-cells [21]. An in vivo study
has investigated the therapeutic potential of targeting CCL3 using atorvastatin in ApoE−/−
mice [26]. Three groups were investigated, chow diet feeding only and two WD fed groups
(16 weeks) of which one was treated with atorvastatin. The study found that atorvastatin
inhibited the 5-LO pathway and downregulated the gene and protein expression of CCL3
significantly attenuating atherosclerotic lesions, in ApoE−/− mice. Taken together, de-
ficiency of CCL3 reduces the atherosclerotic burden, suggesting that blocking of CCL3
maybe using a monoclonal antibody may be a promising therapeutic treatment.
1.3. CCL5-CCR1/CCR5/CCR3
The chemokine CCL5 is also referred to as RANTES and it is known to bind multiple
receptors: CCR1, CCR3 as well as CCR5 [27]. In 2001, platelet derived deposition of CCL5
on activated endothelium was shown to elicit monocyte arrest suggesting a pivotal role
for CCL5 in the development of atherosclerotic lesions [28]. This finding was further
endorsed through a study by Schober et al. disclosing that the monocyte arrest driven
by platelet-derived CCL5 required platelet P-selectin [29]. Moreover, the authors showed
that the systemic inhibition of CCL5 hindered neointima formation as well as macrophage
infiltration in a wire-induced injury model in ApoE−/− mice. Soon after, a study investigated
the effects of systemic CCL5 antagonism via Met-RANTES for 14 weeks in a diet-induced
mouse atherosclerosis [30]. These findings demonstrated a reduction in atherosclerotic
lesions observed in the aortic roots as well as the thoracoabdominal aortas along with a
decline in leukocyte infiltration in Met-RANTES treated mice. The lesions of the control
mice were more abundant in macrophage foam cells as well as T lymphocytes. Altogether,
these findings established that CCL5 fuels atherogenesis by supporting monocyte arrest on
the endothelium and immune cell infiltration into the lesions.
CCL5 is also known to heteromize with the chemokine CXCL4, which is also platelet
derived and deposited onto vascular endothelium [31]. In human atherosclerotic lesions,
CXCL4 was found to correlate with lesion severity and platelet specific deletion of Cxcl4
was found to decrease atherosclerotic lesions in mice [32,33]. A detailed study by Huo
et al. nicely disclosed that platelet derived CCL5 and CXCL4 were delivered to the surface
of vascular endothelium as well as monocytes [34]. Activated platelets supported leukocyte
adhesion to the arterial wall via stimulation of vascular cell adhesion molecule-1 (VCAM-1)
and thereby promoted atherosclerosis. Consistent with these findings, another study
showed that the heterophilic interaction of CCL5 and CXCL4 promoted monocyte arrest
by treating monocytes with the supernatants of activated platelets [35]. Interference with
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the CCL5-CXCL4 heterodimer through a cyclic peptide, named MKEY, was proven to be
beneficial in an mouse model of myocardial infarction as the blockade decreased leukocyte
recruitment as well as the release of neutrophil extracellular traps (NETs) [36]. The study
further reported decreased inflammation and infarction sizes which was associated with
reduced monocyte and neutrophil infiltration into the infarction areas. Additionally, CCL5
can form heteromers with neutrophil-borne human neutrophil peptide 1 (HNP1), which
was also shown to drive monocyte adhesion through CCR5 [37].
Whilst the pro-atherosclerotic role of CCL5 and its heterodimers is clear, studies
dissecting the roles of the CCL5 receptors CCR1 and CCR5 in vascular inflammation show
contradicting results. A diet induced atherosclerotic mouse model study on an ApoE−/−
background showed that genetic deletion of CCR5 resulted in reduced atherosclerotic
lesions along with a more stable plaque phenotype [21]. Within the same study, however,
CCR1 deficiency resulted in increased lesion areas in mice. Nevertheless, others report
significantly decreased plaque sizes in CCR1-deficient ApoE−/− animals after 4 weeks
WD [38]. Hematopoietic CCR1 deficiency on Ldlr−/− background revealed a 70% increase
in atherosclerotic lesion sizes in the thoracic aorta of mice after long term high fat diet
feeding [39]. Ref. [39] These findings indicate that the receptor CCR5 drives atherosclerosis,
whereas the receptor CCR1 is debatable. The atherosclerotic effects of CCR5 were further
demonstrated in a recent, randomized pilot study with human patients [40]. An antagonist
of CCR5, maraviroc, was administered in human immunodeficiency virus (HIV) patients
for 24 weeks and several markers of atherosclerosis were measured as follows: brachial
flow-mediated dilation (bFD), carotid-femoral pulse wave velocity (cFPWV) and carotid
intima-media thickness (cIMT). Further factors, such as systemic inflammatory markers and
monocyte & platelet activation were also examined in the study. Results revealed that CCR5
antagonism through maraviroc significantly improved several markers of atherosclerosis,
such as bFD, cFPWV, and cIMT, whereas systemic inflammation and monocyte activation
were not altered significantly through the treatment. Furthermore, the antagonism study
showed a significant improvement in the vascular competence, which is described as
the ‘ratio of circulating endothelial microparticles (EMPs) to endothelial progenitor cells
(EPCs)’. The authors of this study concluded that CCR5 antagonist maraviroc is protective
against important cardiovascular risk markers, such as endothelial dysfunction and arterial
stiffness. Despite several limitations within the study, these results indicate that CCR5
inhibition may be a promising target in CVD research and further studies are needed
in order to establish a better understanding of its effects. Apart from CCR5 and CCR1,
CCR3 has been shown to be overexpressed in CD68+ macrophage rich areas of human
atherosclerotic lesions, however there is not sufficient information regarding its roles in
atherosclerosis, especially through interaction with CCL5 [41].
1.4. CCL17
CCL17 is elevated in patients with Atopic dermatitis (AD) of all ages and patients
with AD present a greater risk of developing CVD [42,43]. CCL17 has been observed in ad-
vanced human and mouse atherosclerotic lesions [44]. The mostly DC-derived chemokine
CCL17 activates the chemokine receptor CCR4 and was first thought to preferentially
promote T cell responses with a Th2 bias. However, it is now understood that CCL17,
via CCR4, can also attract effector/ memory T cells of the Th1 subtype and also regula-
tory T cells (Tregs) [45]. In atherosclerosis-prone ApoE−/− mice fed a high fat diet for 4
weeks, CCL17 deficiency attenuated atherosclerosis in a Treg-dependent manner. Hence,
vascular CCL17 may recruit T cells along with other proinflammatory molecules expressed
in plaques, as less CD3+ T cells were found in lesions of mice lacking CCL17 [44]. More-
over, adoptive transfer of labeled CD4+ T cells into atherosclerotic ApoE−/− or CCL17-
deficient ApoE−/− mice resulted in more CD4+ T cells homing to aortas of Apoe−/−
mice [44]. Similarly, Foxp3+ Treg expansion but reduced secretion of IL-12 and IL-23
was also observed in an inflammatory colitis model if these animals lacked CCL17 [46].
Hence, CCL17+ DCs in atherosclerotic promote recruitment of inflammatory T cells to
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the vessel wall while restraining Treg maintenance at sites of inflammation and in lym-
phatic organs. In support of this, antibody specific blocking of CCL17 resulted in Treg
expansion and reduced atheroprogression [44]. These data suggests that CCL17 DCs may
regulate homeostatic mechanisms in T cells primarily in lymphoid tissue and regulate Treg
homeostasis in atherosclerosis. A structure-function analysis demonstrated that CC-type
heterodimers can improve chemokine activity, whereas CXC-type heterodimers can inhibit
these functions. Hence, CCL5-CCL17 heterodimers were shown to drive lung injury and
atherosclerosis, however this effect was reversed when a CCL5-derived peptide inhibitor
was used [47]. This CCL5-derived peptide formed a heterodimer with CXCL12, thereby
disrupting the CCL5-CCL17 heterodimer and mimicked the results of a CCL17eGFP/eGFP
mouse model. This demonstrates the atheroprogressive role of CCL17 and suggests
that disruption of chemokine heterodimerization or blocking CCL17 could be a potential
therapeutic target [47].
In line a study of 158 non-coronary artery disease (CAD) patients and 813 CAD patients
showed that CAD patients had higher serum CCL17 levels compared to patients without
CAD [48]. Another study with 794 patients with CAD and 153 without CAD demonstrated
that the T allele at rs223828, which is located in the intron of the CCL17 gene, corresponded
with increased CCL17 serum levels and increased CAD risk [49]. Furthermore, a luciferase
assay showed that the rs223828T allele enhances the CCL17 promoter activity and a ChIP
assays demonstrated that the activator protein-1 (AP-1) was preferentially recruited to the
rs223828 T allele compared with the C allele. The latter fits the notion that AP-1 deficiency
protects against the development of atherosclerosis in hypercholesterolemic mice Thus, it
is suggested that the CCL17 single-nucleotide polymorphisms rs223828 correlates with
increased risk of CAD, via AP-1 activation.
1.5. CCL19, CCL21/CCR7
A clinical study demonstrated that CCL19 and CCL21 was up regulated in carotid
atherosclerosis in 158 patients compared to a control of 20 patients, suggesting an important
role for these chemokines in atherosclerosis [50]. CCL19 mRNA has also been observed
in human atherosclerotic lesions proposing it has a role in atherosclerosis [51]. CCL19 is
secreted by DCs, while both CCL21 and CCL19 are secreted from the endothelium [52,53].
Both of these chemokines share the same receptor CCR7, which is expressed by T cells,
naive B cells, DCs and NK cells [54,55]. Regulation of DC maturation is essential to bal-
ance the protective T cell response and immunopathology. CCL19 induc es a maturation
of DCs, resulting in the upregulation of costimulatory molecules and the production of
pro-inflammatory cytokines which in turn enhances T cell proliferation [56]. Further-
more, CCL19-induced DCs preferentially induce a Th1 rather than a Th2 response. The
upregulation of a Th1 response further drives the progression of atherosclerosis [56,57].
Isolation of DCs from mice deficient in CCL19 and CCL21 (plt/plt) had only a partially
mature phenotype, stressing the importance of these chemokines for full DC maturation
in vivo [56]. However, in vitro experiments showed that oxLDL reduced both gene and
protein expression of CCR7 on DCs and CCL21 protein expression on human microvascu-
lar endothelial cells (HMECs) [58]. This suggests that retention of DCs in atherosclerotic
plaques correlates with the downregulation of chemokines and their ligands, known to
regulate DC migration. These DCs may then drive the inflammatory response in atheroscle-
rosis and enhance the risk for plaque rupture. Thus, modulation of DC maturation may
prove to be a promising therapeutic treatment.
Examinations in vitro demonstrated the ability of CCL21 to promote lipid accumula-
tion in macrophages while CCL19 induces SMC proliferation and matrix metalloprotein-1
expression [50]. This suggests that these chemokines may also directly contribute to the de-
velopment of atherosclerosis. CCL19 stimulated HUVECs for example facilitate monocyte
adhesion and migration, whereas CCL21 only induced migration but not adhesion [59].
The same study also showed that clinically achievable concentrations of atorvastatin sup-
pressed CCL19/CCL21/CCR7 expression and inhibited CCL19/ CCL21-induced monocyte
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adhesion and migration [59]. However further research is required in vivo to determine the
CCL19/CCL21/CCR7 role in the recruitment and infiltration of monocytes in atherosclero-
sis and to determine its therapeutic potential.
The role of CCL19 and CCL21 in experimental atherosclerosis in mice is still disputed
as results from different studies are contradictory. In an ApoE−/−CCR7−/− mouse model,
were mice were fed a WD for 8 weeks, the lesion size was increased due to an increase
in T cell infiltration into the atherosclerotic lesions and the blood, bone marrow, and
spleen [60]. In an adoptive transfer experiment T cells from ApoE−/−CCR7−/− mice
migrated poorly into lymph nodes but better into mouse aortas compared to T cells from
CCR7-competent animals, suggesting that CCL19 and CCL21 facilitate T cell homing
to lymphatic orangs thereby exhibiting atheroprotective functions [60]. However, in an
Ldlr−/− mouse model, where mice were fed a high-cholesterol diet for 12 weeks, the
adoptive transfer of wild-type T cells resulted in atheroprogression in Ldlr−/−CCR7−/−
mice while transfer of CCR7-deficient T cells into Ldlr−/−CCR7−/− mice did not result in
increased lesion formation [61]. This suggests that CCR7 is atheroprogressive by mediating
CCR7-dependent T-cell priming in secondary lymphoid organs and CCR7-dependent T cell
homing to the atherosclerotic lesion. In a bone marrow transplant experiment of CCL21-
deficient bone marrow into Ldlr−/− animals it was further demonstrated that CCL21
coordinates the homing of leukocytes into atherosclerotic lesions, whereas CCL19 influences
the activation of leukocytes, lipid uptake of macrophages and foam-cell formation [62].
Taken together studies in ApoE−/− animals reveal a protective role of CCR7 while reports
in Ldlr−/− mice report an atheroprogressive role of this receptor. These conflicting results
may be due to the different mouse models used or due to systemic knockout of the CCR7 in
ApoE−/− versus adoptive transfer and bone marrow transplantation in Ldlr−/− animals.
Further investigations on the role of these chemokines in vivo are needed.
1.6. CXCL1-CXCR2
Chemokines are involved in all stages of atherosclerosis with various roles. As men-
tioned above, endothelial dysfunction is a major starting point of lesion formation. Once
the vascular endothelium is activated, it secretes inflammatory markers to recruit immune
cells. The chemokine axis CXCL1(GRO-alpha or KC)/CXCR2 was shown to be especially
important in the initiation phase of atherosclerotic lesion development. In 1994, Schwartz
et al. suggested that a GRO homologue was involved in monocyte binding to minimally
modified LDL (MM-LDL) stimulated human aortic endothelial cells (HCAECs) [63]. The au-
thors reported that the mRNA expression of CXCL1 levels as well as the surface expression
of a protein binding to CXCL1-antibodies were significantly increased in HCAECs upon
MM-LDL exposure. Moreover, administration of an antibody against CXCL1 inhibited
the monocyte binding to HCAECs and interestingly heparin treatment on ECs (releasing
heparin-bound molecules from the cell surface) resulted in the inhibition of both CXCL1
expression as well as monocyte binding. Collectively, these results suggested that a specific
type of CXCL1 was expressed on the surface of ECs and mediated monocyte binding
to the activated endothelium. This role of GRO/CXCL1 was later confirmed in a study
using a flow chamber system, which facilitates ex-vivo perfusion studies on the carotid
arteries extracted from ApoE−/− mice that are susceptible to developing atherosclerotic
lesions. The authors reported that CXCL1 significantly governed monocyte arrest on en-
dothelium [64]. Both anti-CXCL1 antibody blocking, as well as the blocking of its receptor
CXCR2, abolished the observed monocyte arrest on the endothelium suggesting that this
axis plays an important role in monocyte accumulation on atherosclerotic endothelium.
These findings were carried forward with an in-vivo model study, which inves-
tigated the impact of CXCL1 on atherosclerosis using CXCL1-deficient Ldlr−/− mice.
After 16 weeks of high fat diet CXCL1-deficient Ldlr−/− mice exhibited significantly
less atherosclerotic lesions in their aortas as well as aortic valves compared to control
mice [65]. Moreover, immunohistochemical staining of the aortic valves revealed di-
minished macrophage accumulation in the lesions of CXCL1 deficient mice. The study
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additionally examined the role of leukocyte specific CXCL1 via bone marrow transplanta-
tion. Hematopoietic deficiency of CXCL1 did not alter atherosclerosis, suggesting that the
atherosclerotic effects of CXCL1 were attributable to non-hematopoietic cells. Interestingly,
they had previously shown that the deficiency of the CXCL1 receptor CXCR2 in the bone
marrow of Ldlr−/− mice resulted in significantly reduced atherosclerotic lesions along
with decreased lesional macrophage accumulation at the end of a 16-week high fat diet,
suggesting a pro-atherosclerotic role for leukocyte specific CXCR2 [66].
Another study assessing ApoE−/− mice on eight weeks of high fat versus chow diet
reported that CXCL1 levels were significantly increased in the sera of high fat diet fed
mice [38]. This was associated with higher numbers of classical monocytes in the circulation
of these animals together with a decrease in the bone marrow, suggesting that CXCL1 plays
a key role in hypercholesterolemia induced monocytosis. The authors then studied the
effects of CXCL1 neutralization with antibody injections during four weeks of high fat diet
in ApoE−/− mice and revealed a significant decrease in monocytosis in comparison to
control mice. Furthermore, CXCL1 neutralization led to decreased atherosclerotic lesions
in the aortic roots, as well as reduced monocyte and macrophage counts in the aortas
of the mice [38]. These findings clearly indicate the importance of the CXCL1/CXCR2
axis in classical monocyte recruitment under hyperlipidemic conditions, which is a potent
atheroprogressive event and therefore a promising therapeutic target.
1.7. CXCL4
CXCL4 (also platelet factor 4, PF4) was initially identified as a product of activated
platelets but is now known to be secreted by a variety of immune cells [67]. CXCL4 has
a broad range of biological functions including induction of respiratory burst in human
monocytes accompanied by secretion of several chemokines such as CCL3, CCL4, and
CXCL8 [68]. However, in atherosclerosis CXCL4 prevents monocyte apoptosis and pro-
motes macrophage differentiation from human peripheral blood monocytes [69]. Differenti-
ation plays a key role in the progression of atherosclerosis or the recovery, as demonstrated
by both in vitro and in vivo data. Typically macrophages exhibit two phenotypes, the
M1 phenotype promotes atherosclerosis whereas the M2 plays a more protective role [70,
71]. CXCL4 acts on macrophages in a unique way developing a non-characteristically
macrophage phenotype, this CXCL4 lineage is referred to as M4 [72]. The CXCL4 in-
duced macrophage phenotype shares similarities with both M1 and M2 macrophages.
Specifically 375 genes were differentially expressed between M-CSF and CXCL4 induced
macrophages of these, 206 genes were overexpressed in CXCL4 macrophages and are im-
plicated in the inflammatory/immune response, antigen processing and presentation, and
lipid metabolism [72]. Interestingly, M4 loses the capability to phagocytose zymosan beads.
In the M4 phenotype scavenger receptors expression was reduced whereas cholesterol
efflux transporters showed higher expression compared to M-CSF induced macrophages,
resulting in lower LDL content. However, the role of CXCL4 on the development of foam
cells in vivo has yet to be determined.
In addition, CXCL4-induced macrophages further lack the expression of the hemoglobin
scavenger receptor CD163 [73]. CD163 is a scavenger receptor for hemoglobin and
hemoglobin– haptoglobin (Hb-Hp) complexes, which upregulates the enzyme heme
oxygenase-1 that reportedly protects from atherosclerosis [74]. Although M4 macrophages
share characteristics of both M1 and M2 they still possess an overall pro-atherogenic ef-
fect, as the deletion of the PF4 gene encoding for CXCL4 results in reduced lesion size in
atherosclerotic ApoE−/− mice [33]. This demonstrates that CXCL4 has a significant role in
the development of atherosclerosis. More research is needed to understand the role of the
M4 phenotype in atherosclerosis and its potential as a therapeutic target. Furthermore, the
receptor for CXCL4 is still disputed as many potential receptors have been investigated
but none was conclusively identified as of today [73,75].
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1.8. CXCL8
A key aspect of atherosclerosis is the oxidation of LDL which is recognized by the
immune system as a danger signal and results in the release of CXCL8 [76]. CXCL8 (also
IL-8) is an important inflammatory factor involved in many inflammatory responses and
diseases including the development of atherosclerosis [77]. CXCR1 and CXCR2 recognize
CXCL8, but CXCR2 displays higher affinity towards CXCL8 [78]. Recently, CXCL8 has
been identified as a critical regulator in the function of ECs and vascular SMCs. Therefore,
it is likely to participate in the development of atherosclerosis [79]. One study showed that
a siRNA for the Transmembrane protein 98 (TMEM98) inhibits CXCL8 mediated leukocyte
adhesion to the endothelium by down-regulating Intercellular Adhesion Molecule 1 (ICAM-1)
expression on ECs. Furthermore, it also inhibits the proliferation and migration of vascular
SMCs through suppressing the AKT/GSK3β/Cyclin D1 signaling pathway. These actions
synergistically could reduce the development of atherosclerosis, but would require further
investigation in vivo. In an in vitro study, CXCL8 enhances the expression of miR-183,
which then inhibits ABCA1 expression and cholesterol efflux, suggesting that the CXCL8-
miR-183-ABCA1 axis may play an transitional role in the development of foam cells in
atherosclerosis [80]. Thus, CXCL8 may influence the development of atherosclerosis via
the inhibition of cholesterol efflux protein ABCA1 thereby promoting the development of
foam cells. Further research is needed to understand this in an in vivo setting.
An in vivo experiment assessed the potential for CXCL8 as a therapeutic target. ApoE−/−
mice on high fat diet for 12 weeks were injected subcutaneously with CXCL8(3-72)K11R (G31P),
a human CXCL8 analog in which the 11th amino acid (AA) lysine was substituted to
arginine and the 31st AA glycine was substituted to prolineG31P [81,82]. Although mice do
not possess the CXCL8 gene they do express KC/GRO-a belonging to the GRO chemokines,
and the human G31P can function in mice [83]. G31P reduced the serum concentration
of LDL-C, and decreased the secretion of keratinocyte chemoattractant and the gene ex-
pression of MMP-2, MMP-9, Proliferating cell nuclear antigen (PCNA), and Myocyte
Enhancer Factor 2a (Mef2a). Furthermore, G31P also inhibited the gene expressions of
p-ERK, ROCK1, ROCK2, and decreased the calcium concentrations in the A7r5 cell line,
in vitro. These factors inhibit the proliferation and migration of VSMCs through regulating
the Rho-kinase, ERK, and calcium-dependent pathways, and therefore inhibit the develop-
ment of hyperlipidemic conditions. This suggests that G31P suppresses the development of
atherosclerosis by antagonizing the CXCL8 receptor. In abdominal aortic aneurysm (AAA)
the CXCR1/2 antagonist DF2156A disrupted CXCL8 signaling reversing the formation
of AAA, and prevented matrix degradation in the murine elastase model [84]. Patients
with atherosclerosis show a higher serum level of CXCL8 and neutrophil extracellular
traps (NETs) [85]. CXCL8 interacted with its receptor CXCR2 on neutrophils, leading to
the formation of NETs via Src and extracellular signal-regulated kinase (ERK) and p38
mitogen-activated protein kinases (MAPK) signaling to aggravate atherosclerosis progres-
sion in vivo [85]. In summary, CXCL8 plays an important role not only in atherosclerosis
but also in other vascular diseases and may be a promising therapeutic target.
1.9. CXCL9-CXCL10-CXCL11/CXCR3
Increased levels of CXCL9, CXCL10, and CXCL11 can be detected in human atheroscle-
rotic lesions throughout all stages of plaque development [6]. Endothelial cells and
macrophages can release CXCL9, CXCL10 and CXCL11 all of which share the receptor
CXCR3 [86]. CXCR3 activation facilitates the recruitment and homing of active Th-1 cells
to the site of plaque development or rupture [86,87]. However, the different chemokines
of CXCR3 have slightly different roles in T cell trafficking, as CXCL9/CXCL10 activate a
different signaling cascade than CXCL11 [88].
CXCL10 is expressed by T cells and monocytes and facilitates T cell retention within
the lesion [89]. CXCL11 is able to induce the chemotaxis of mature CXCR3+ T but not
resting or naïve T cells suggesting that CXCL11 only plays a role during pro-inflammatory
conditions [90]. Furthermore, CXCL11 has been found to induce the down-regulation
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of CXCR3 expression on T cells after they have been in contact with interferon-activated
endothelial cells [91]. This could serve as an arrest signal for the activated T cells thereby
limiting the inflammatory responses [92]. CXCL11 does also interact with the atypical
chemokine receptor ACKR3 leading to CXCL11 internalization which could represent a
way of regulating CXCR3-mediated responses [93]. However, the precise role of CXCL11
in atherosclerosis has not been addressed so far. CXCL9 and CXCL10 both promote
inflammation by inducing T cell polarization into Th-1/Th-17 cells, whereas CXCL11 drives
the development of Treg cells to counter regulate inflammation [88]. Interestingly, the loss
of CXCR3 via targeted deletion or pharmacological inhibition resulted in reduced plaque
formation, diminished recruitment of Th-1 cells and increased migration of Tregs to lesions
of ApoE−/− mice receiving a WD for 10 weeks [94,95]. Furthermore, ApoE−/− CXCL10−/−
mice fed a WD for either 6–12 weeks exhibited reduced atherogenesis and greater numbers
of Treg cells in the lesion [96], while antibody-mediated CXCL10 inhibition in ApoE−/−
mice increased plaque stability [7]. In line with this, CXCL10 is associated with the
development of vulnerable plaque in humans [97]. Taken together, interfering with CXCR3
and CXCL10 seems to exert atheroprotective function while the full picture of how this
receptor mediates effects induced by its different ligands still needs further investigation.
1.10. CXCL12-CXCR4/ACKR3
CXCL12 (SDF-1) is described as a ‘primordial’ chemokine due to its essential roles
in homeostasis and development, such as leukocyte homing and recruitment, stem cell
recruitment as well as vascularization [98–101]. This chemokine signals through the
receptors CXCR4 and ACKR3 (CXCR7), both of which are also essential for healthy cardiac
development [102–105]. In 2007, GWAS analyzed chromosomal loci associated with CAD
in humans and exposed novel loci which markedly contribute to CAD as well as myocardial
infarction [106]. This study identified key genes that are of high importance in CVD and
among those CXCL12 was one of the novel candidates. Other studies have also shown that
circulating CXCL12 levels were associated with CAD severity as well as heart failure and
its increase in circulation is recognized as a CVD risk factor [107–109].
Early studies examining the role of CXCL12 in vascular biology established that
this chemokine promoted healing of the injured vascular tissue. CXCL12 was shown
to boost in vivo EC progenitor recruitment in ischemic tissues via injections of CXCL12
locally to ischemic hindlimbs of mice. The findings led to the conclusion that CXCL12
endorsed ischemic neovascularization [110]. Further evidence from other studies showed
that CXCL12 supported neointimal formation in carotid arteries as a result of CXCL12-
dependent SMC recruitment in a wire induced vascular injury model using ApoE−/−
mice [111]. A recent study by Döring and colleagues dissected the role of CXCL12 in
atherosclerosis by establishing a comprehensive cell-specific deficiency of the chemokine in
ApoE−/− mice [109]. The authors examined lesion areas in aortas as well as aortic arches
in addition to macrophage and collagen content of the lesions in five different models of
CXCL12 deficiency: ubiquitous knockout, hematopoietic knockout, non-hematopoietic
knockout, SMC knockout, as well as EC-specific knockout. Whilst systemic deficiency of
the chemokine did not affect lesion size or composition, its non-hematopoietic deficiency
improved atherosclerosis. This effect was then mirrored by the EC-specific knockout of the
chemokine, which decreased lesion sizes in the aortas as well as the aortic arches whereas
increasing the collagen content within the lesions. This outcome was observed along with
a systemic decrease of circulating CXCL12 levels leading to the conclusion that EC-derived
CXCL12 promotes atherosclerosis [109].
The importance of the CXCL12–CXCR4 axis in vascular remodeling was shown
by identifying its contribution to neointimal hyperplasia through recruitment of bone
marrow derived SMC progenitors [112]. The CXCL12-CXCR4 axis was also studied in the
context of atherosclerosis with a focus on CXCR4 using diet-induced atherosclerosis mouse
models [20]. According to the study, Cxcr4 deficiency in the bone marrow of ApoE−/−
mice increased atherosclerotic lesion sizes and constant blockade of systemic CXCR4
Cells 2021, 10, 226 12 of 26
via its antagonist AMD3465 led to higher numbers of circulating leukocytes, especially
neutrophils, leading to a higher content of neutrophils within atherosclerotic lesions.
Furthermore, AMD3465 treated mice had significantly less SMCs in their lesions. Thus,
the authors concluded that interfering with the CXCL12–CXCR4 axis enhanced neutrophil
recruitment to atherosclerotic lesions, which then stimulated lesion growth and instability.
These results pointed toward a protective role of CXCL12-CXCR4 in atherosclerosis. It is
worth mentioning, however, that this study did not specifically target the ligand induced
effect of CXCR4, rather the deficiency of CXCR4 itself. Apart from CXCL12, macrophage
migration inhibitory factor (MIF) can also bind to CXCR4 and the findings of this study can
therefore not be attributed to a specific ligand of CXCR4. A study targeting this gap was
published by Akhtar et al. in 2013 [113]. The authors partially ligated carotid arteries of
ApoE−/− mice and repeatedly injected CXCL12. They observed that the CXCL12 injections
led to more stable plaque phenotypes compared to control mice; lesional macrophage
content was decreased, whereas SMCs and collagen content was increased along with
thicker fibrous caps. Interestingly, CXCL12 injections did not have an impact on lesion sizes
per se. However, it should be mentioned that lesions of ligated arteries are phenotypically
different from those of normal vessels.
The role of CXCR4, specifically in the artery, in a diet induced atherosclerosis mouse
model was further assessed by Döring et al. using cell specific deletions of the receptor
in endothelial cells and SMCs [114]. In contrast to their findings regarding EC-specific
CXCL12, EC-specific CXCR4 was shown to limit atherosclerosis by supporting endothelial
barrier function. According to their study, EC-specific deficiency of the receptor led to
arterial leakage and thereby promoted arterial leukocyte invasion. Furthermore, their
study established an association of a C-allele at rs2322864 within the CXCR4 locus with
increased risk for CHD in a regression analysis using human data from 92,516 CHD cases
and 167,280 controls [114]. Another study investigating the effects of the CXCL12–CXCR4
axis in a hypercholesterolemia mouse model using black 6 (BL6) mice and revealed that
mice fed with high fat diet had higher levels of CXCL12 in their circulation along with
leukocytosis [115]. This finding was similar to the results of human studies, which the
authors thought to be a result of disturbed CXCL12-CXCR4 interaction in the bone marrow
due to high cholesterol levels. They have also shown that LDL treatment of human umbili-
cal vascular endothelial cells (HUVEC) led to increased CXCL12 production [115]. Others
have also revealed evidence linking the CXCL12 receptor ACKR3 to lipid metabolism [116].
Through genetic ablation of ACKR3 in mice with a wire induced vascular injury as well as
ACKR3 ligand (CCX771) treatment in ApoE−/− mice on high fat diet, Li et al. showed that
ACKR3 promoted cholesterol uptake into adipose tissue and thereby controlled systemic
lipid levels. However, this study does not disclose through which biological ligand ACKR3
exerted these effects.
Monocyte to macrophage differentiation is a key step supporting macrophage driven
oxLDL clearance in the arterial intima, which eventually leads to the aggregation of
foam cells and therefore fatty streaks. Interfering with this step by means of preventing
macrophage accumulation may be a key to inhibit fatty streak formation. Therefore, key
regulators of monocyte to macrophage differentiation can be viewed as a therapeutic target
to impede atherogenesis. In an in vitro study, CXCL12 was shown to be secreted by human
monocytes and the inhibition of either CXCR4 or ACKR3 via their antagonists significantly
decreased CD163 expression of monocytes [5]. Moreover, CXCL12 treatments showed a
decrease in RUNX3 and TGF-ß transcription in these cells, whereas CXCR4 antagonism
through AMD3100 allowed RUNX3 expression. These findings indicate that monocyte-
derived CXCL12 controls monocyte to macrophage differentiation in an autocrine manner
by down-regulating the transcription factor RUNX3. These findings need further confirma-
tion in in vivo models. Mice lacking CXCL12 specifically in the monocyte subset may be a
good tool to study the impact of CXCL12 on cell differentiation.
Evidence on CXCL12 suggests a pro-atherosclerotic role of the chemokine, whereas
its receptors seem to play varying roles. Further studies are needed to improve the under-
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standing of each axis in atherosclerosis. Whilst CXCL12 can bind two different receptors,
its receptors can also be activated by additional ligands which increases the complexity
and complicates conclusions to be drawn. Moreover, cell-specific effects of these axes
vary, which is yet another strain in the path to map the roles of these chemokine-receptor
interactions in this multidimensional disease.
1.11. CXCL16-CXCR6
CXCL16 is an unusual chemokine as it contains a mucin-like stalk, and transmembrane
and cytoplasmic domains not found in other CXC chemokines [117]. The mucin-like stalk
is also susceptible to cleavage releasing the chemokine domain, which acts to chemoattract
CXCR6-expressing T, NK, NKT, B, and dendritic cells [117]. CXCL16 is expressed on
stimulated ECs and SMCs, macrophages, DCs, and platelets, whereas its receptor CXCR6 is
expressed on leukocyte subtypes [118,119]. It has been suggested that CXCR6 is a reliable
marker of IFNG producing effector CD4 T cells, which drive Th1-mediated diseases like
atherosclerosis [120]. In an ApoE−/− mouse model where CXCR6 was replaced with a
green fluorescent protein CXCR6GFP/GFP, a decrease in atherosclerosis was observed when
compared with ApoE−/− mice [121]. This reduction in atherosclerosis was attributed
to a reduction of CXCR6+ T cells within the aortas. Further experiments demonstrated
that CXCR6 is necessary for the recruitment of CXCR6+ leukocytes into the lesions. This
reduction of CXCR6+ T cells within the aortas lead to a weakened production of INF-
γ and a reduction of CD11b+/CD68+ macrophages in the aorta. CXCL16 is involved
in multiple phases of the immune response, from antigen recognition to migration and
infiltration of immune cells into sites of inflammation, including the atherosclerotic plaque.
CXCL16 is also expressed on the plasma membrane directly mediating adhesion to cells
expressing the receptor CXCR6 [118]. This cell-to-cell adhesion could conceivably facilitate
the development of plaques in atherosclerosis. In a recent report it has been shown
that platelets from the blood are able to adhere to the inflammatory chemokine CXCL16
expressed by the endothelium [122]. Hence, CXCL16 as well as platelet CXCR6 act as
potent peripheral blood mononuclear cell adhesion ligands to the atherosclerosis prone
vessel wall and thus promote the progression of atherosclerosis [123].
CXCL16 may also directly play a role in the development of foam cells as the expres-
sion of CXCL16 has been found to be upregulated in lipid-laden intimal macrophages
and SMCs [124]. Originally, CXCL16 was identified due to its ability to scavenge phos-
phatidylserine and oxLDL and thus was originally considered to be a scavenger recep-
tor [124,125]. Recently, CXCL16 has been shown to act as a scavenger receptor for oxLDL
uptake on hepatic cells and results in the formation of foam cells in Non-alcoholic fatty
liver disease [126]. Macrophages are not the only cell type to develop into foam cells,
SMCs are also capable of accumulating lipids and take on a foamy appearance. In human
atherosclerotic lesions CXCL16 is expressed in SMCs and it has been demonstrated that
IFN-G is a potent CXCL16 inducer of itself in human aortic SMCs in vitro [127]. IFN-G
induction of CXCL16 correlated with an increased uptake of oxLDL into these cells [127].
Therefore, it can be concluded that in vivo CXCL16 could facilitate the development of
SMC foam cells, but this warrants further investigation.
CXCL16 is also expressed on HUVECs and LPS induces the overexpression of CXCL16
along with TLR4, NF-κB and miR-146a but this induction can be blocked by the TLR4
inhibitor TAK-242 [128]. Additionally, either the overexpression or inhibition of miR-146a
either inhibited or increased the LPS-induced expression of CXCL16, TLR4 and NF-κB
protein production, respectively. Finally, the miR-146a-induced expression of CXCL16
was blocked by TAK-242. Thus, in HUVECs LPS stimulates CXCL16 expression via the
TLR4/NF-κB signaling pathway, and simultaneously, miR-146 negatively regulates LPS-
induced CXCL16 expression through a TLR4-dependent mechanism. An in vivo study
demonstrated that the expression of CXCL16 was upregulated in atherosclerotic ApoE−/−
mice fed a high fat diet, compared with control ApoE−/− mice fed a normal diet [129]. The
expression levels of TRL4, IL-1 receptor-associated kinase 1, TNF-α, NF-κB, and IL-1β were
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also significantly upregulated in atherosclerotic ApoE−/− mice compared with control
mice. However, the expression of miR-146a and miR-146b was significantly downregulated
in atherosclerotic ApoE−/− mice compared with control ApoE−/− animals. This suggests
that CXCL16 may regulate the TRL4/NF-κB/CXCL16 signaling pathway, and that miR-
146a and miR-146b may negatively regulate CXCL16 via TRL4/NF-κB signaling. However,
further investigations in vivo are needed to identify the therapeutic potential of treating
atherosclerosis via the inhibition of either TLR4 or miR-146a.
Previous clinical studies demonstrated that the serum levels of CXCL16 increase
during atherosclerotic ischemic stroke and are higher in patients who exhibit microem-
bolic signals compared to microembolic signals-negative patients [130,131]. In another
clinical study 43 patients with end stage renal disease (ESRD) were separated into either
the control group or the inflamed group based on their plasma C-reactive protein (CRP)
levels; a control (CRP < 3.0 mg/L) and an inflamed group (CRP ≥ 3.0 mg/L) [130,132].
The inflamed group presented an increase in both MCP-1 and TNF-α protein expression
and macrophage infiltration in radial arteries. Additionally, there was a significant in-
crease in foam cell formation in the radial arteries of the inflamed group compared to the
control. Immunohistochemical and immunofluorescence staining of these radial arteries
of the inflamed group further showed that protein expression of CXCL16, CXCR6, and
ADAM10 was increased. CXCL16 expression also correlated with P2X7R expression in the
radial arteries of ESRD patients. This suggests that inflammation contributes to foam cell
development in the radial arteries of ESRD patients via activation of the CXCL16/CXCR6
pathway, and is possibly regulated by P2X7R. Therefore, P2X7R may as well be a potential
therapeutic target for atherosclerosis.
1.12. CX3CL1-CX3CR1
CX3CL1 and its receptor CX3CR1 are important for immune cell trafficking [133].
CX3CL1 is expressed as a membrane bound protein (mCX3CL1) the extracellular domain
can be cleaved and released to act at distal sites [134]. CX3CL1 acts as a monocyte survival
molecule as CX3CL1 and CX3CR1 deficient mice had a significant reduction of Gr1low
blood monocyte levels under both steady-state and inflammatory conditions [135]. Use
of the Bcl2 transgene restored the wild-type phenotype, providing genetic evidence that
the CX3CR1/L1 axis provides an essential cell survival signal [135]. Thus, loss of either
CX3CL1 or CX3R1 could lead to monocyte apoptosis thereby effectively reducing the devel-
opment and even regression of atherosclerotic lesion formation. CX3CL1 upregulation has
also been observed in macrophage-rich human coronary artery plaques and several studies
have demonstrated that genetic deletion of either CX3CL1 or CX3CR1 protects mice against
atherosclerosis [135–137]. This suggests CX3CL1 plays a pivotal role in atherosclerosis both
in the early and late stages of the disease. During atherosclerosis, monocytes expressing
CX3CR1 bind and adhere to the endothelium, which expresses mCX3CL1 [138]. Certainly,
CD16+CX3CR1HIGH monocytes enhanced endothelial STAT1 and NFκB p65 phosphoryla-
tion resulting in an upregulated expression of CX3CL1 and IL-1β, and ICAM1 and VCAM1,
compared to classical CD14+ monocytes [139]. This describes the mechanism by which
CX3CR1 and its ligands can increase cardiovascular risk. Furthermore, a recent study
has highlighted a novel model of CD8 T cell involvement in atherosclerosis. Whereby
CX3CL1 and IL-15 synergistically activate the vascular endothelium to promote infiltration
of CX3CR1+ memory CD8 T cells which further promote endothelial inflammation [140].
This interaction may be prevalent in aging and in HIV populations where circulating
activated CX3CR1+ CD8 T cell numbers are often higher.
Treatment of Ldlr−/− mice with a CX3CL1-Fc fusion protein, which interferes with the
CX3CR1-CX3CL1 interaction, significantly reduced atherosclerotic lesions size independent
of changes in cholesterol levels [141]. The same study demonstrated that in vitro using
HUVEC, CX3CL1-Fc interferes with monocyte binding and in vivo it reduces leukocyte
rolling and adhesion in murine capillaries [141]. This leads to a decrease in M1-like
macrophages and T cells in the aortic wall, potentially decreasing chronic inflammation in
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the lesions. Hence, the long-acting CX3CR1 agonist prevents monocytes from adhering
to the endothelial wall thereby reducing lesion formation offering potential therapeutic
options.
Another study examined the potential therapeutic value of targeting vascular CX3CL1/
CX3CR1 [142]. They transplanted the aortic segments from Cx3cr−/−ApoE−/− into
ApoE−/− mice which resulted in reduced atherosclerotic plaque formation compared
to ApoE−/− or Cx3cr1−/−ApoE−/− mice after receiving transplantation of ApoE−/− aor-
tas. This suggests that CX3CR1 on vascular cells plays a key role in plaque formation and
progression. Recently a DNA vaccine, which targets CX3CR1 in ApoE−/− was tested and
resulted in an induction of anti-CX3CR1 antibodies [143]. Vaccinated mice exhibited a
significantly reduced atherosclerotic plaque in the brachiocephalic artery. This was due to a
reduction of macrophage accumulation and a reduction in lipid deposition, however there
was no change to the M1 phenotype predominantly found in inflamed lesion. This suggests
that the vaccine mainly limited macrophage infiltration. Overall, targeted DNA vaccina-
tion to CX3CR1 was well tolerated by the mice, inducing a strong immune response and
attenuation of atheromatous plaque size. Overall, vaccination against certain chemokines
may offer some therapeutic potential for the treatment of atherosclerosis.
1.13. MIF-CXCR2/CXCR4/ACKR3
Macrophage migration inhibitory factor (MIF) is now well known to be a pro-atherogenic
cytokine which is also characterized as an atypical chemokine and it binds multiple
chemokine receptors: CXCR2, CXCR4, and ACKR3 [144]. A study in rabbits demon-
strated that MIF is upregulated in atherogenesis and later it was established that MIF is
present in human atherosclerotic lesions with regards to various cell types [144,145].
An in vivo study revealed that monoclonal antibody based blocking of MIF in ApoE−/−
mice reduced aortic intimal macrophage content in addition to circulating inflammatory
molecules, such as IL-6 [146]. Furthermore, local expression of inflammatory molecules
in the aortic wall, such as ICAM-1, IL-12, and TNF-α, were also reduced in MIF antibody
treated mice. Although these findings are known to significantly influence atherosclerotic
lesion development, MIF blockade did not significantly alter lesion sizes compared to
control mice in this study, despite a decrease. Another study, however, studying genetic
ablation of MIF in Ldlr−/− mice disclosed a highly significant reduction in atherosclerotic
lesion sizes in the abdominal aortas of MIF deficient mice along with decreased intimal
thickening in aortic arches [147]. Consistent with these findings, another study reported
reduced vascular inflammation and neointimal thickening upon neutralizing MIF in an
atherosclerotic mouse model with experimental angioplasty [148]. In addition to vascular
inflammation, MIF was also demonstrated to influence plaque stability after vascular
injury in ApoE−/− mice. Schober et al. reported reduced foam cell content along with an
increase in smooth muscle cell content as well as collagen in the lesions of mice treated with
neutralizing monoclonal MIF antibody [149]. Via in vitro flow assays, the authors further
confirmed that MIF treated aortic endothelium exhibited increased monocyte recruitment
and oxLDL driven monocyte arrest could be inhibited by monoclonal antibody treatment,
suggesting that endothelial MIF mediates oxLDL triggered monocyte arrest. In addition
to CXCL1, MIF can also signal through CXCR2 and it has also been shown to mediate
monocyte arrest through CXCR2 [150]. Additionally, this study has also reported that
immobilized MIF on aortic endothelial cells can elicit effector T cell arrest, which could
be inhibited by CXCR4 blockade. Moreover, MIF is also shown to mediate monocyte
chemotaxis through CXCR2 as well as B-cell migration through ACKR3 [150,151]. Collec-
tively, these data demonstrate the spectrum of numerous inflammatory roles of MIF which
significantly contribute to atherosclerosis and therefore the importance of this chemokine
as a therapeutic target.
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Table 1. Overview of the inflammatory chemokines and their role in murine atherosclerosis
Chemokine axis (Mouse) Model Treatment Outcome Ref.
CCL2-CCR2
C57/Bl6 Thioglycollate (i.p.) injection Reduced monocyte recruitment [11]
CCL2−/− Ldlr−/− 12 weeks WD Smaller lesions, reduced recruitment [12]
CCL2−/− Apoe−/− & CCL2−/− bone marrow into
Apoe3 Leiden mice
5–13 weeks WD Smaller lesions, reduced recruitment [13–15]
Apoe−/− 4 weeks WD, CCR2 Antagonist RS102895 Smaller lesions, less macrophages [16]
CCR2−/− Apoe−/− WD, Cuff placement Reduced neointimal formation [17–19]
CCL3
Ldlr-/ transplanted with CCL3−/− BM 12 weeks WD Reduced lesion size [25]
Apoe−/− Atorvastatin, 16 weeks WD





Apoe−/− Wire injury, inhibition of CCL5 Reduced neointima formation [29]
Apoe−/− 14 weeks WD, Met-Rantes (CCL5 inhibitor)
Smaller lesions and reduced lesional number of
macrophages and T cells [30]
Apoe−/−
CCL5-CXCL4 heterodimer blocking with
MKEY Reduced scar formation in MI [36]
CCR5−/− Apoe−/− WD Reduced lesion size [21]
CCR1−/− Apoe−/− WD Increased lesion size [21]
CCR1−/− Apoe−/− 4 weeks WD Reduced lesion size [38]
CCL17
CCL17e/e Apoe−/− 4 and 12 weeks WD Reduced lesion size, increased number of Treg [44]
Apoe−/− WD, CCL5-CCL17 heterodimer inhibition Smaller lesions [47]
CCL19,
CCL21/CCR7
ApoE−/−CCR7−/− 8 weeks WD Increased lesion size and T cell number [60]
Ldlr−/−CCR7−/−
12 weeks WD, adoptive transfer of wild type
T cells Increased lesion size [61]
CCL19−/− CCL21−/−BM into Ldlr−/− WD Increased plaque stability, no change in lesion size [62]
Cells 2021, 10, 226 17 of 26
Table 1. Cont.
Chemokine axis (Mouse) Model Treatment Outcome Ref.
CXCL1-CXCR2
Cxcl1−/− Ldlr−/− 16 weeks WD Reduced lesion size, less macrophages [65]
Cxcl1−/− BM into Ldlr−/− 16 weeks WD No effect [65]
Cxcr2−/− BM into Ldlr−/− 16 weeks WD Reduced lesion size, less macrophages [66]
Apoe−/− 8 weeks WD versus chow diet
Increased levels of CXCL1 in the serum, more
monocytes in the circulation [38]
Apoe−/−
CXCL1 neutralization with antibody
injections, 4 weeks WD
Reduced lesion size, decreased monocyte
mobilization [38]
CXCL4 PF4−/− Apoe−/− WD Reduced lesion size [33]
CXCL8 Apoe−/−
Injection of human CXCL8 analog, WD 12
weeks Reduced lipid levels, reduced lesions? [81]
CXCL12-
CXCR4/ACKR3
Nude mice Injectionof CXCL12 into hindlimb of mice Induces ischemic neovascularization [110]
Apoe−/− Vascular injury SMC-derived CXCL12 mediates neointima formation [111]
Apoe−/− lacking CXCL12 specifically in ECs WD 12 weeks Reduced lesion formation [109]
Ldlr−/− with CXCR4−/− BM, or Apoe−/− with
CXCR4 blocking
WD, AMD3465 Enhanced lesion formation [20]
Apoe−/− WD and repetitive CXCL12-injections
More stable plaque phenotype in partial ligation, no
size differences [113]
Apoe−/− lacking CXCR4 in ECs or SMCs specifically WD 12 weeks Enhanced lesion formation, higher permeability [114]
C57/Bl6 4 weeks high cholesterol diet Higher CXCL12 levels [115]
ACKR3−/− Apoe−/− Wire induced vascular injury, WD
Enhanced peripheral cholesterol levels, increased
neointima [116]
CXCL16-CXCR6
CXCR6GFP/GFP ApoE−/− WD Reduced lesion size, less T cells and macrophages [121]
Apoe−/− WD versus Chow diet Upregulation of CXCL16 under WD [125]
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Table 1. Cont.
Chemokine axis (Mouse) Model Treatment Outcome Ref.
CX3CL1-
CX3CR1
Apoe−/− with CX3CR1−/− BM 12 weeks WD Induces monocyte apoptosis, reduces lesion size [135]
CX3CL1−/− Apoe−/−
CX3CL1−/− Ldlr−/−
~12 weeks WD Reduced lesion size and monocyte recruitment [136]
Ldlr−/−
Injection of a long lasting FcCX3CL1 version,
agonist, WD Reduced lesion size and monocyte recruitment [141]
Apoe−/−
Transplantation of aortic segments from
Cx3cr−/−ApoE−/− into ApoE−/− Plaque regression [142]
Apoe−/−
DNA vaccine which induces antibodies




Apoe−/− MIF antibody blocking Reduced macrophage load in lesions [147]
MIF−/− Ldlr−/− WD Reduced lesion size [148]
Apoe−/− (vascular injury) MIF antibody blocking Reduced inflammation and intimal thickening [149,150]
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2. Recent Highlights and the Road Ahead
Chemokines and their receptors are being studied continuously in the research of
atherosclerosis. Although numerous axes still remain to be elucidated, the quantity of
studies dissecting the roles of various chemokine-receptor axes is fairly rich. Therefore, it
is necessary to recapitulate these findings in a condensed as well as an up-to-date manner.
In this review, we highlighted several new studies which provided significant evidence
advancing the research of chemokine function in atherosclerosis. For example, CCL2 was
recently shown to be released onto the arterial endothelium rhythmically by myeloid cells
oscillating in a circadian fashion [16]. This finding presented a novel approach called
‘chrono-pharmacological treatment strategy’ targeting the peaks of pro-atherosclerotic
myeloid cell action. Taken further this study emphasizes to reschedule complicated surg-
eries to times where less CCL2 is released. Another recent mouse study presented protective
and anti-inflammatory effects of MKEY (a specific peptide blocking the CCL5-CXCR4 inter-
action) in a myocardial ischemia/reperfusion injury model and suggested that it could be
used therapeutically in atherosclerosis and myocardial infarction treatment [36]. A human
study investigated the impact of CCR5 antagonist maraviroc in patients with HIV on
several cardiovascular risk markers and found these to be reduced, suggesting a need for
further studies on maraviroc’s effects on CVD [40]. Further, An et al. showed that CXCL8
contributes to atherosclerosis development by driving neutrophil extracellular trap (NET)
formation via CXCR2 [85]. The study also showed that CXCR2 inhibition successfully
abrogated NET formation in human neutrophils, proposing that neutrophil specific inter-
ference with CXCR2 could hold therapeutic options. The association between CXCL12 and
CAD [107] was also carried further by the findings that endothelial deficiency of CXCL12
decreased atherosclerotic lesion sizes in mice whilst increasing lesion stability through le-
sional collagen content, establishing a pro-atherosclerotic role of endothelial CXCL12 [109].
Further, examining the impact of CX3CR1–CX3CL1 axis inhibition via a soluble CX3CR1
agonist revealed improved atherosclerosis via the inhibition of monocyte-endothelial cell
interaction and suggested this approach as a treatment strategy for atherosclerosis [141].
Taken together following up on chemokine/chemokine receptor axis in chronic vascular
inflammation still reveals promising and future-orientated insights and mechanisms which
may allow for therapeutic targeting to utilize treatments to dampen chronic inflammation
in CVD as an addition to lipid lowering therapies.
3. Conclusions
Chemokines are essential in orchestrating the development of atherosclerosis, from the
initial stage of endothelial dysfunction, chemokines like CXCL1 act as a chemoattractant
for several immune cells (Figure 1). After aiding the homing of these cells to the lesions,
chemokines like CXCL8 activate the endothelial barrier by increasing adhesion molecules
to allow the infiltration of various immune cells. Moreover, chemokines like CXCL16
directly act as adhesion molecules to the CXCR6 expressed on platelets. Even after immune
cells have infiltrated into the intima chemokines then dictate their phenotype, like CXCL4
which establishes the unique M4 macrophage phenotype, promoting the development of
atherosclerosis (Figure 2). Foam cell development, a key feature of atherosclerosis, is also
controlled by chemokines as for example CXCL16 directly facilitates the development of
foam cells from macrophages acting as scavenger ligands for oxLDL (for an overview of
the murine studies please also refer to Table 1).
Nevertheless, future work is necessary to understand the role of CXCL16 in the
formation of foam cells from SMCs. Finally, establishment of a fibrous cap around the
lesions to ensure stability and prevent rupture may be influenced by CXCL10 concentrations
which impact on fibrous cap thickness. Taken together, many aspects of chemokines and
their role within atherosclerosis have still to be answered, such as the receptor for CXCL4
still remains elusive.
With respect to therapeutic targeting one has to keep in mind that receptors can
be activated by many chemokines in some cases with varying outcomes. Cell specific
Cells 2021, 10, 226 20 of 26
therapeutic targeting of specific chemokines may be therefore the most promising approach
in tackling atherosclerosis. Thus, chemokines continue to be an exciting avenue of research
with potential real-world implications in atherosclerosis treatment.
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